{"componentChunkName":"component---src-templates-chapter-level-2-chapter-level-2-tsx","path":"/topics/depression-in-children/prescribing-information/fluoxetine/","result":{"pageContext":{"chapter":{"id":"db0404ff-2d68-5309-ae1b-14a947c530c8","slug":"fluoxetine","fullItemName":"Fluoxetine","depth":2,"htmlHeader":"<!-- begin field dce85605-fe84-4d09-ab55-4835798c8459 --><h2>Fluoxetine</h2><!-- end field dce85605-fe84-4d09-ab55-4835798c8459 -->","summary":"","htmlStringContent":"<!-- begin item 0c8e7cc4-0d00-4cd2-9612-7a03afe6e338 --><!-- end item 0c8e7cc4-0d00-4cd2-9612-7a03afe6e338 -->","topic":{"id":"101ea2c8-5f55-5359-aeda-5b20ef97f370","topicId":"088b8823-67f3-4e08-81f1-8778bd49b12e","topicName":"Depression in children","slug":"depression-in-children","lastRevised":"Last revised in  August 2020","chapters":[{"id":"f64dd2b3-170d-5d9b-aecb-1a2978ecb4e1","fullItemName":"Summary","slug":"summary","subChapters":[]},{"id":"e6e1d043-84eb-5268-9881-e9206a00a233","fullItemName":"Have I got the right topic?","slug":"have-i-got-the-right-topic","subChapters":[]},{"id":"5e95ca6c-8f50-5b31-b155-739311de5b50","fullItemName":"How up-to-date is this topic?","slug":"how-up-to-date-is-this-topic","subChapters":[{"id":"f3f0affc-e4a2-56b0-b121-2d69b1330cca","slug":"changes","fullItemName":"Changes"},{"id":"3f5587ad-b1bc-595c-b884-a355ab80031e","slug":"update","fullItemName":"Update"}]},{"id":"bca87a5c-ec4c-59fd-8119-690fc138098f","fullItemName":"Goals and outcome measures","slug":"goals-outcome-measures","subChapters":[{"id":"d5cd25b2-ada4-5e22-ab78-d6e7ccafcc1b","slug":"goals","fullItemName":"Goals"},{"id":"bccddba5-ed7c-5703-8bc4-1b28d9f71a65","slug":"outcome-measures","fullItemName":"Outcome measures"},{"id":"e573d49b-c962-5303-bd62-b82571b44692","slug":"audit-criteria","fullItemName":"Audit criteria"},{"id":"401ddd2b-4d39-590d-bf30-3f0ae316aa98","slug":"qof-indicators","fullItemName":"QOF indicators"},{"id":"a11520a5-7bf1-5125-ad47-8de75dacf931","slug":"qipp-options-for-local-implementation","fullItemName":"QIPP - Options for local implementation"},{"id":"ac1d9e5a-89af-5a06-9fec-f25790730559","slug":"nice-quality-standards","fullItemName":"NICE quality standards"}]},{"id":"718734a7-182f-5c62-a63f-c92f735a79cd","fullItemName":"Background information","slug":"background-information","subChapters":[{"id":"79daa524-8b5f-5f8e-91d5-9619e12c21c7","slug":"definition","fullItemName":"Definition"},{"id":"cd4207fb-6b8f-54fa-a48d-31239d2789d1","slug":"risk-factors","fullItemName":"Risk factors"},{"id":"e78ff9ac-1f1b-5cc4-bb2d-333c32dbfcb2","slug":"prevalence","fullItemName":"Prevalence"},{"id":"1ffa8456-d989-5f53-9716-0d11c36fa70e","slug":"complications","fullItemName":"Complications"},{"id":"e48963ee-be38-527e-877e-feb582ba484e","slug":"prognosis","fullItemName":"Prognosis"}]},{"id":"b343ac53-3d02-5f80-ab1d-7797d497d60b","fullItemName":"Diagnosis","slug":"diagnosis","subChapters":[{"id":"d0d025ab-d9fe-561b-80e3-4bd77255243c","slug":"general-principles-of-care","fullItemName":"General principles of care"},{"id":"83af9e65-d83a-5c2f-b4d3-6a8598e15100","slug":"assessment","fullItemName":"Assessment"},{"id":"f076b5d2-7785-5b8a-8164-72a53569465d","slug":"diagnosis","fullItemName":"Diagnosis"}]},{"id":"6b07e3a8-4308-50d3-a53d-02ca763c90ac","fullItemName":"Management","slug":"management","subChapters":[{"id":"b5a30131-c1a5-5aae-8cc1-bc0ecc447842","slug":"mild-depression","fullItemName":"Scenario: Mild depression"},{"id":"065fa4ec-6b6a-55c7-b85d-48d27bdb24a6","slug":"moderate-to-severe-depression","fullItemName":"Scenario: Moderate to severe depression"},{"id":"2340e96a-ed85-521c-9aec-fa96883b76f2","slug":"detection-risk-profiling","fullItemName":"Scenario: Detection and risk profiling"}]},{"id":"6af92bf2-aadd-59da-8421-3a1cd891e218","fullItemName":"Prescribing information","slug":"prescribing-information","subChapters":[{"id":"db0404ff-2d68-5309-ae1b-14a947c530c8","slug":"fluoxetine","fullItemName":"Fluoxetine"}]},{"id":"9d3f64e8-54c8-5927-8f13-8ff5d6455f14","fullItemName":"Supporting evidence","slug":"supporting-evidence","subChapters":[]},{"id":"932982e2-2ddc-58a3-a6e2-08e641df0776","fullItemName":"How this topic was developed","slug":"how-this-topic-was-developed","subChapters":[{"id":"eae6b677-230c-5938-8679-07f4b635cf04","slug":"search-strategy","fullItemName":"Search strategy"},{"id":"b264f482-a47e-52c8-9351-13efb6390eb4","slug":"stakeholder-engagement","fullItemName":"Stakeholder engagement"},{"id":"fb199ddd-0a39-5f4b-ae69-077340eaa28a","slug":"evidence-exclusion-criteria","fullItemName":"Evidence exclusion criteria"},{"id":"24d74131-55e0-59a8-9133-2b6e89eefc72","slug":"organizational-behavioural-financial-barriers","fullItemName":"Organizational, behavioural and financial barriers"},{"id":"74499613-5204-5d1c-8dd6-3c4114d8be0d","slug":"declarations-of-interest","fullItemName":"Declarations of interest"}]},{"id":"79146846-65ae-5cb8-a7ee-097ffc31c035","fullItemName":"References","slug":"references","subChapters":[]}]},"parentChapter":{"id":"6af92bf2-aadd-59da-8421-3a1cd891e218","slug":"prescribing-information","fullItemName":"Prescribing information"},"subChapters":[{"id":"71831df2-c266-5064-af4c-b12b3a73c8c9","slug":"general-prescribing-information","fullItemName":"General prescribing information","depth":3,"htmlHeader":"<!-- begin field a9066069-1432-4786-89e7-aaec00b6386c --><h3>What do I need to know about fluoxetine treatment for children with depression?</h3><!-- end field a9066069-1432-4786-89e7-aaec00b6386c -->","summary":"","htmlStringContent":"<!-- begin item 4abde87c-62b3-4213-917a-aaec00b63825 --><!-- begin field 652b7f9a-9b82-4e53-92b3-aaec00b6386c --><ul><li><strong>Fluoxetine is the preferred antidepressant </strong><strong>for treating moderate and severe depression in children (5–11 years) and young people (12–18 years).</strong> It is the only antidepressant where the benefits outweigh the risks. <ul><li>Fluoxetine should only be prescribed to children and young people with moderate to severe depression following an assessment and diagnosis by a child and adolescent psychiatrist.</li><li>It should not be offered except in combination with a concurrent psychological intervention. If psychological intervention is declined, antidepressants may still be given, but as the child or young person will not be reviewed at psychological intervention sessions, the prescribing doctor should closely monitor their progress on a regular basis and focus particularly on emergent adverse effects. </li></ul></li><li><strong>The starting dose of fluoxetine for a child (5–11 years) or young person (12–18 years) with depression should be 10 mg daily. </strong><ul><li>This can be increased to 20 mg daily after 1 week if clinically necessary, although lower doses should be considered in children of lower body weight.</li><li>There is little evidence regarding the effectiveness of doses higher than 20 mg daily; however, higher doses may be considered in older children of higher body weight and/or when, in severe illness, an early clinical response is considered a priority.</li></ul></li><li><strong>Specific arrangements must be made, by the prescribing doctor and the healthcare professional delivering the psychological intervention, for careful monitoring of adverse effects, as well as for reviewing the mental state and general progress of the child or young person. </strong><ul><li>Weekly contact is recommended for the first 4 weeks of treatment. The precise frequency should be decided on an individual basis and recorded in the notes.</li><li>The child or young person should be closely monitored for the appearance of suicidal behaviour, self‑harm, or hostility, particularly at the beginning of treatment.</li><li>Unless it is felt that the treatment needs to be started immediately, symptoms that might be subsequently interpreted as adverse effects should be monitored for 7 days before prescribing.<ul><li>Once treatment is started, the child or young person and/or their family/carers should be informed that if there is any sign of new symptoms of these kinds, urgent contact should be made with the prescribing doctor. </li></ul></li></ul></li><li><strong>If a child or young person is responding to fluoxetine, </strong>treatment should be continued for at least 6 months after remission (defined as no symptoms and full functioning for at least 8 weeks). Treatment should continue for 6 months beyond this 8-week period.</li><li><strong>Where fluoxetine is to be discontinued,</strong> it should be phased out over a period of 6–12 weeks with the exact dose being titrated against the level of discontinuation/withdrawal symptoms.</li></ul><p>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/depression-in-children/references/\">NICE, 2019</a>]</p><!-- end field 652b7f9a-9b82-4e53-92b3-aaec00b6386c --><!-- end item 4abde87c-62b3-4213-917a-aaec00b63825 -->","subChapters":[]},{"id":"04870534-3827-55d2-9130-cb3a391530f3","slug":"contraindications-cautions","fullItemName":"Contraindications and cautions","depth":3,"htmlHeader":"<!-- begin field 020ee35e-615d-4445-8e14-4e56184165a5 --><h3>Whar are the contraindications and cautions for fluoxetine?</h3><!-- end field 020ee35e-615d-4445-8e14-4e56184165a5 -->","summary":"","htmlStringContent":"<!-- begin item e7da9a52-a886-4b64-ae43-f8747e91fa68 --><!-- begin field d70af524-158c-4f25-a10e-15150219a533 --><ul><li><strong>Fluoxetine should not be used in children or young people with:</strong><ul><li>Poorly controlled epilepsy (fluoxetine should not be used if the person enters a manic phase).</li></ul></li><li><strong>Fluoxetine should be used with caution in children or young people with:</strong><ul><li>Cardiac disease.</li><li>Concurrent electroconvulsive therapy.</li><li>Diabetes mellitus.</li><li>Epilepsy (discontinue if convulsions develop).</li><li>History of bleeding disorders (especially gastro-intestinal bleeding).</li><li>History of mania.</li><li>Susceptibility to angle-closure glaucoma.</li></ul></li></ul><p>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/depression-in-children/references/\">Joint Formulary Committee, 2019</a>]</p><!-- end field d70af524-158c-4f25-a10e-15150219a533 --><!-- end item e7da9a52-a886-4b64-ae43-f8747e91fa68 -->","subChapters":[]},{"id":"9796279a-0726-5139-89fd-e14e206c5e19","slug":"adverse-effects","fullItemName":"Adverse effects","depth":3,"htmlHeader":"<!-- begin field 6a5fefe9-b060-4cd5-91a8-21b71978f205 --><h3>What are the adverse effects of fluoxetine?</h3><!-- end field 6a5fefe9-b060-4cd5-91a8-21b71978f205 -->","summary":"","htmlStringContent":"<!-- begin item 5a6e46c4-17a1-48d6-b990-5aa63db66778 --><!-- begin field 45936813-877b-4cb0-8210-07f65d5241a9 --><ul><li><strong>Adverse effects associated with fluoxetine are dose related. The most common adverse effects</strong> are chills, feeling abnormal, uterine disorder, vasodilation, and blurred vision.</li><li><strong>Suicidal behaviour has been linked with the use of antidepressants, particularly in children and young people. </strong><ul><li>Children and young people should be monitored for suicidal behaviour and risk of self-harm, particularly at the beginning of treatment or if the dose is changed. </li></ul></li><li><strong>Other adverse effects of fluoxetine include:</strong><ul><li>Uncommon — abnormal thinking, altered temperature sensation, altered mood, cold sweat, dysphagia, dyspnoea, hypotension, muscle twitching, and self-injurious behaviour.</li><li>Rare or very rare — buccoglossal syndrome, leucopenia, neutropenia, oesophageal pain, pharyngitis, respiratory disorders, serum sickness, speech disorder, and vasculitis.</li><li>Frequency not known — bone fracture.</li></ul></li></ul><p>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/depression-in-children/references/\">Joint Formulary Committee, 2019</a>]</p><!-- end field 45936813-877b-4cb0-8210-07f65d5241a9 --><!-- end item 5a6e46c4-17a1-48d6-b990-5aa63db66778 -->","subChapters":[]},{"id":"f9d38fa4-2b92-582b-87e6-222fdb3d50bb","slug":"drug-interactions","fullItemName":"Drug interactions","depth":3,"htmlHeader":"<!-- begin field 5c46da55-d6c1-4119-a41b-8ca80abde037 --><h3>Fluoxetine drug interactions</h3><!-- end field 5c46da55-d6c1-4119-a41b-8ca80abde037 -->","summary":"","htmlStringContent":"<!-- begin item 9116ade9-edcb-4ff2-815d-1f57446588a0 --><!-- begin field 2e66b557-cad7-4c00-8a94-9cfd572f5fb4 --><ul><li><strong>Drug interactions with fluoxetine include:</strong><ul><li><strong>Antiepileptics</strong> — fluoxetine is predicted to increase the concentration of fosphenytoin and phenytoin.<ul><li>Manufacturer advises monitor and adjust dose.</li></ul></li><li><strong>Aspirin and nonsteroidal anti-inflammatory drugs (such as ibuprofen)</strong> — increased risk of bleeding. In addition, both fluoxetine and ibuprofen can increase the risk of hyponatraemia.</li><li><strong>Omega-3-acid ethyl esters</strong> — predicted to increase the risk of bleeding events when given with fluoxetine.<ul><li>Manufacturer advises use with caution or avoid.</li></ul></li><li><strong>Tramadol </strong>— fluoxetine is predicted to decrease the efficacy of tramadol.<ul><li>Manufacturer makes no recommendation.</li></ul></li><li><strong>Warfarin</strong> — predicted to increase the risk of bleeding events when given with fluoxetine.<ul><li>Manufacturer advises use with caution or avoid.</li></ul></li></ul></li><li><strong>For a complete </strong><strong>list of possible drug interactions with fluoxetine</strong><strong>, </strong>see the <a data-hyperlink-id=\"5d1bd39e-1a5d-4822-a304-a98f017ff9da\" href=\"http://scribe.clarity.co.uk/www.medicines.org.uk/emc\">electronic Medicines Compendium</a> (eMC) or the <a data-hyperlink-id=\"eadda68c-df0e-46e1-aaa7-a98f017ffaca\" href=\"https://bnf.nice.org.uk/\">British National Formulary</a> (BNF).</li></ul><p>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/depression-in-children/references/\">Joint Formulary Committee, 2019</a>]</p><!-- end field 2e66b557-cad7-4c00-8a94-9cfd572f5fb4 --><!-- end item 9116ade9-edcb-4ff2-815d-1f57446588a0 -->","subChapters":[]},{"id":"b9b467b6-821b-5707-aade-d9d5059a623a","slug":"patient-information","fullItemName":"Patient information","depth":3,"htmlHeader":"<!-- begin field 06c49ffc-64d8-4f61-ab8f-ab0400a49f97 --><h3>What information and advice should be given to a child or young person taking fluoxetine and/or their family/carers?</h3><!-- end field 06c49ffc-64d8-4f61-ab8f-ab0400a49f97 -->","summary":"","htmlStringContent":"<!-- begin item 3359eada-d36d-4e77-965e-ab0400a49f60 --><!-- begin field e3ab4162-6d3e-464e-a559-ab0400a49f97 --><ul><li><strong>Advise the child or young person and/or their family/carers:</strong><ul><li>To be vigilant for worsening depressive symptoms and suicidal ideas, particularly when starting the treatment and at times of increased personal stress. They should seek help promptly if they are concerned.</li><li>That it usually takes 2–4 weeks for symptoms to improve, although some people improve within a few days of treatment.</li><li>That antidepressant treatment should be taken for at least 6 months after they have recovered, to reduce the risk of relapse. People who are at high risk of relapse may need to take them for longer than this.</li><li>That antidepressant drugs are not addictive.</li><li>That fluoxetine should be taken as prescribed and should not be stopped suddenly. This helps to prevent discontinuation symptoms (such as dizziness, nausea, paraesthesiae, anxiety, diarrhoea, flu-like symptoms, and headaches) from occurring. </li><li>That although fluoxetine has no or negligible influence on the ability to drive and use machines and has been shown not to affect psychomotor performance, any psychoactive drug may impair judgement or skills. The young person should, therefore, avoid driving a car or operating hazardous machinery until they are reasonably certain that their performance is not affected by fluoxetine.</li></ul></li></ul><p> [<a class=\"bibliography-reference internal-reference\" href=\"/topics/depression-in-children/references/\">ABPI, 2019</a>]</p><!-- end field e3ab4162-6d3e-464e-a559-ab0400a49f97 --><!-- end item 3359eada-d36d-4e77-965e-ab0400a49f60 -->","subChapters":[]}]}}},"staticQueryHashes":["3666801979"]}